[go: up one dir, main page]

WO2010062038A2 - Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same - Google Patents

Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2010062038A2
WO2010062038A2 PCT/KR2009/006050 KR2009006050W WO2010062038A2 WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2
Authority
WO
WIPO (PCT)
Prior art keywords
isomer
tyrosine kinase
pharmaceutical composition
composition containing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006050
Other languages
French (fr)
Korean (ko)
Other versions
WO2010062038A3 (en
Inventor
양범석
김선영
조종운
이향숙
우성호
박태교
김용주
김승태
이홍범
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Ligachem Biosciences Inc
Original Assignee
Korea Institute of Science and Technology KIST
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST, Legochem Biosciences Inc filed Critical Korea Institute of Science and Technology KIST
Publication of WO2010062038A2 publication Critical patent/WO2010062038A2/en
Publication of WO2010062038A3 publication Critical patent/WO2010062038A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to a compound expressed in the following chemical formula 1, to an isomer thereof, or to a pharmaceutically allowable salt thereof. The compound expressed in chemical formula 1 inhibits the tyrosine kinase activity of Discoidin Domain Receptor 1 (DDR1) and Discoidin Domain Receptor 2 (DDR2), and thus can be valuably used in the prevention or treatment of diseases such as a cancer, hepatocirrhosis, arteriosclerosis, rheumatoid arthritis, osteoarthritis, and the like, which are known to be mainly caused by an excessive activation of Discoidin Domain Receptor 1 or Discoidin Domain Receptor 2.
PCT/KR2009/006050 2008-11-27 2009-10-20 Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same Ceased WO2010062038A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080118850A KR101126736B1 (en) 2008-11-27 2008-11-27 Tyrosine kinase inhibitory compounds, isomers thereof or pharmaceutical acceptable salts thereof, and pharmaceutical composition comprising the same
KR10-2008-0118850 2008-11-27

Publications (2)

Publication Number Publication Date
WO2010062038A2 true WO2010062038A2 (en) 2010-06-03
WO2010062038A3 WO2010062038A3 (en) 2010-07-22

Family

ID=42226201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006050 Ceased WO2010062038A2 (en) 2008-11-27 2009-10-20 Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same

Country Status (2)

Country Link
KR (1) KR101126736B1 (en)
WO (1) WO2010062038A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
CN103087077A (en) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
JP2013538223A (en) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー Azabenzothiazole compounds, compositions and methods of use
CN103360407A (en) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 Thiophene miazines derivate as well as preparation method and medical application thereof
JPWO2015060373A1 (en) * 2013-10-23 2017-03-09 中外製薬株式会社 Quinazolinone and isoquinolinone derivatives
WO2018171726A1 (en) * 2017-03-23 2018-09-27 高雄医学大学 Discoidin domain receptor 1 inhibitor and activator and use thereof
WO2021239643A1 (en) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Benzylamine derivatives as ddrs inhibitors
EP4032896A1 (en) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2023210599A1 (en) * 2022-04-25 2023-11-02 日本新薬株式会社 Compound serving as ddr1 kinase inhibitor, and medicine
US12133896B2 (en) 2017-03-23 2024-11-05 Kaohsiung Medical University Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540051B1 (en) * 2013-11-27 2015-07-28 한국과학기술연구원 Composition for preventing skin aging or improving skin condition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0831829T3 (en) * 1995-06-07 2003-12-15 Pfizer Heterocyclic, ring-condensed pyrimidine derivatives
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
PL340589A1 (en) * 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
BR0308162A (en) * 2002-03-01 2004-12-07 Pfizer Thienopyridine indolyl urea derivatives useful as antiangiogenic agents and methods for their use

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
US9062066B2 (en) * 2010-05-26 2015-06-23 Korea Institute Of Science And Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
JP2013538223A (en) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー Azabenzothiazole compounds, compositions and methods of use
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN103087077A (en) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivative, its preparation method and application in medicines
WO2013064068A1 (en) * 2011-11-03 2013-05-10 上海希迈医药科技有限公司 Thienopyrimidine and furopyrimidine derivatives, preparation method thereof and medical use thereof
CN103087077B (en) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically
WO2013068836A1 (en) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
CN103360407A (en) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 Thiophene miazines derivate as well as preparation method and medical application thereof
CN103360407B (en) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 A kind of Thienopyrimidine analog derivative, its preparation method and in application pharmaceutically
JPWO2015060373A1 (en) * 2013-10-23 2017-03-09 中外製薬株式会社 Quinazolinone and isoquinolinone derivatives
EP3061749A4 (en) * 2013-10-23 2017-05-31 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2018171726A1 (en) * 2017-03-23 2018-09-27 高雄医学大学 Discoidin domain receptor 1 inhibitor and activator and use thereof
US10946021B2 (en) 2017-03-23 2021-03-16 Kaohsiung Medical University Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1)
US12133896B2 (en) 2017-03-23 2024-11-05 Kaohsiung Medical University Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein
WO2021239643A1 (en) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Benzylamine derivatives as ddrs inhibitors
EP4032896A1 (en) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2022157166A1 (en) 2021-01-20 2022-07-28 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2023210599A1 (en) * 2022-04-25 2023-11-02 日本新薬株式会社 Compound serving as ddr1 kinase inhibitor, and medicine

Also Published As

Publication number Publication date
WO2010062038A3 (en) 2010-07-22
KR101126736B1 (en) 2012-04-12
KR20100060300A (en) 2010-06-07

Similar Documents

Publication Publication Date Title
WO2010062038A2 (en) Tyrosine kinase inhibitor compound, isomer thereof or pharmaceutically allowable salt thereof, and pharmaceutical composition containing the same
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
UA94622C2 (en) Kinase innhibitor
WO2006138660A3 (en) Sphingosine kinase inhibitors
WO2011052923A3 (en) Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
NZ623069A (en) Heat shock protein binding compounds, compositions, and methods for making and using same
MX2012013197A (en) Indazole inhibitors of kinase.
WO2012028332A8 (en) Pharmaceutically active compounds as axl inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
EP2617414A3 (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2010021918A8 (en) Compounds as kinase inhibitors
MX2011013325A (en) 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
PL1899329T3 (en) Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
MX2009011579A (en) Pyrimidinones as casein kinase ii (ck2) modulators.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2